On the other hand, our results agree with several works showing that various immunomodulatory treatments increase CD39 expression in peripheral Treg cells from RR-MS patients, including corticoids19, fingolimod17,20, alemtuzumab21 and IFNβ15. This evidence concerns the gene ENTPD1 and myeloid sarcoma.